IP Library Granted Patent US 9,982,014
Granted Patent B2
US 9,982,014 · App. 15/031,135 · Granted May 29, 2018

Tetrapeptide compound and method for producing same

Inventors: Yoshinori Hirai (Takasago, JP); Akira Nishiyama (Takasago, JP); Masaru Mitsuda (Takasago, JP)
Assignees: Kaneka Corporation; Stealth BioTherapeutics Corp
C07K5/1021C07K5/1019A61K38/00C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,982,014
App. No.
15/031,135
Granted
May 29, 2018
Kind
B2
Abstract

The present invention is to provide a method for the efficient production on an industrial scale of SS-31 (D-Arg-Dmt-Lys-Phe-NH 2 ), which is an SS peptide. According to the present invention, the desired SS-31 is produced by efficiently synthesizing a tetrapeptide compound as a precursor of SS-31 and improving the tetrapeptide purity by crystallization.

Claims (15)

1. A tetrapeptide compound represented by the following formula (1)

where R is a hydrogen atom, benzyl group, or benzyloxycarbonyl group.

2. The tetrapeptide compound according to claim 1 , which is an intermediate for producing a peptide drug represented by the following formula (2)

3. The tetrapeptide compound according to claim 1 , where R is a hydrogen atom.

4. The tetrapeptide compound according to claim 1 , where compound (1) is an amorphous solid.

5. The tetrapeptide compound according to claim 1 , wherein the compound is in the form of a crystalline solid and exhibits one or more peaks at 2θ±0.1 selected from 5.4°, 10.5°, 15.6°, 17.6°, 18.0°, 18.6°, 20.1°, or 20.6° in a powder X-ray diffraction spectrum obtained using Cu-Kα radiation.

6. The tetrapeptide compound according to claim 1 , wherein compound (1) is in a form of an amorphous solid or a crystalline solid.

7. A method for producing a peptide pharmaceutical, characterized in that the tetrapeptide compound represented by the following formula (1)

is catalytically reduced in the presence of a palladium catalyst to produce a peptide pharmaceutical represented by the following formula (2)

wherein in formula (1), R is a hydrogen atom, benzyl group, or benzyloxycarbonyl group.

8. The production method according to claim 7 , characterized in that compound (1) is produced by condensation via a carbodiimide compound in the presence of a hydroxylamine compound or via a dehydrocondensation agent of Z-D-Arg(Z)2-OH represented by the following formula (3)

and the tripeptide compound represented by the following formula (4)

9. The production method according to claim 7 , wherein R is a hydrogen atom.

10. The production method according to claim 7 , wherein compound (1) is a solid precipitated from an aprotic polar solvent.

11. The production method according to claim 10 , wherein the aprotic solvent is at least one selected from tetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide, N,N-diethylformamide, N,N-dipropylformamide, N,N-dibutylformamide, dimethylsulfoxide, N-methylpyrrolidone, and 1,3-dimethylpropylene urea.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2021
From: STEALTH BIOTHERAPEUTICS CORP
To: STEALTH BIOTHERAPEUTICS INC.
Reel/Frame 058164/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2018
From: HIRAI, YOSHINORI; NISHIYAMA, AKIRA; MITSUDA, MASARU
To: KANEKA CORPORATION; STEALTH PEPTIDES INTERNATIONAL, INC
Reel/Frame 045624/0545 →
CHANGE OF NAME Recorded Apr 24, 2018
From: STEALTH PEPTIDES INTERNATIONAL, INC
To: STEALTH BIOTHERAPEUTICS CORP
Reel/Frame 046008/0927 →
Priority Claims (1)
JP 2013-220655 · Oct 23, 2013 · national
Continuity (1)
Related Publication 20160264623A1 · Sep 15, 2016